Asymmetrex Ready to Do a Number for Hematopoietic Stem Cell Transplantation Therapies
To prepare the field of regenerative medicine for its AlphaSTEM stem cell counting technology, Asymmetrex makes good on its earlier promise to post on the RegMedNet Industry Developments page an expose on the vexing, but silent, nature of the HSC counting problem in HSCT medicine. Because no earlier technology for counting HSCs has been available, HSCT is the one field of medicine that is unable to determine the dose of its most important medicine, HSCs. Asymmetrex relates the clinical implications of this long-standing shortcoming, in particular how it impacts dire HSCT with umbilical cord blood. To learn more visit RegMedNet.